Background Previous studies have been interpreted as suggesting an increase in risk of cancer among users of calcium-channel blockers compared with users of bêta-blockers.
To explore this issue further, we studied a large group of hypertensive patients to investigate the relation of calcium-channel blockers and cancer.
Methods In cohorts of users of calcium-channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, and bêta-blockers, we identified all cases of cancer diagnosed in 1995.
We used a nested case-control analysis to estimate the risk of cancer among users of calcium-channel blockers and ACE inhibitors, with users of bêta-blockers as a reference group.
The study was based on information taken from the General Practice Research Database, and the study population was restricted to patients with at least 4 years of medical history recorded on computer.
Findings The study was based on 446 cases of cancer and 1750 controls.
The relative risk estimates for all cancers combined were 1.27 (95% Cl 0.98-1.63) and 0.79 (0.58-1.06) for users of calcium-channel blockers and ACE inhibitors, respectively, relative to users of bêta-blockers.
There was little difference in risk estimates with duration of use of calcium-channel blockers of less than 1.0 year (relative risk 1.46), 1.0-3.9 years (1.26), and 4.0 years or more (1.23). (...)
Mots-clés Pascal : Antagoniste calcium, Bloquant bêta-adrénergique, Antagoniste, Récepteur bêta-adrénergique, Inhibiteur angiotensin converting enzyme, Tumeur maligne, Risque, Toxicité, Médicament, Homme, Epidémiologie
Mots-clés Pascal anglais : Calcium antagonist, Beta blocking agent, Antagonist, bêta-Adrenergic receptor, ACE inhibitor, Malignant tumor, Risk, Toxicity, Drug, Human, Epidemiology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0191785
Code Inist : 002B02U10. Création : 21/05/1997.